Silo Pharma (NASDAQ: SILO) received a Notice of Allowance from the U.S. Patent and Trademark Office for a key patent supporting its lead asset, SPC- ...
The Emily Program, a nationally recognized leader in eating disorder treatment, today announced the launch of its 2025 Learn with Emily webinar series. The year-long initiative provides in-depth ...
Cingulate Inc. (NASDAQ:CING) announced the successful completion of its final FDA-required study for CTx-1301 (dexmethylphenidate) aimed at treating Attention Deficit Hyperactivity Disorder (ADHD).
Swisher said the clinic fulfills a high-demand area of intensive outpatient programs considered “lacking” — mental health — while most of the surrounding programs focus on substance ...